Co-Founders of American Academy of Anti-Aging Medicine Laud Value of Nymox's Alzheimer's Developments.

Business &Medical Editors

KENSINGTON, Md.--(BUSINESS WIRE)--Feb. 2, 2000

Dr. Robert Goldman and Dr. Ronald Klatz, co-founders of the American Academy of Anti-Aging Medicine, laud the research into the cause of Alzheimer's Disease and tests to aid in its diagnosis developed by Nymox Pharmaceutical Corp. (Nasdaq:NYMX) in the new edition of their widely praised book on the brain and aging: &uot;Brain Fitness,&uot; published by Doubleday.

The latest edition of the book, co-authored with science writer Lisa Berger, summarizes and evaluates pioneering research by Nymox in the identification and establishment of the role of spherons in the Alzheimer's disease process. &uot;All in all, the theory that spherons lead to the senile plaques of Alzheimer's disease satisfies some twenty criteria of validity in explaining many of the characteristics of senile plaques and Alzheimer's,&uot; the book says. &uot;It is thought that the bursting of spherons sets off a cascade of neural damage that in turn leads to the release of more spherons and the death of still more nerve cells, until the destruction begins to manifest itself in the first signs of the cognitive decline and dementia of Alzheimer's.&uot;

The book continues, &uot;Spherons offer more than a theory of the cause of Alzheimer's disease; they also offer the hope for the first effective treatment of this dread illness. Experimental drugs have been found that stop the conversion of the burst spheron into the massive area of destruction associated with senile plaque. Instead the burst spheron remains relatively intact and able to be removed from the tissue by the body's normal housekeeping process before it can become a deadly plaque.&uot;

The book also evaluates the efficacy of Nymox's AD7C(TM) test, used as a diagnostic aid for the detection of Alzheimer's disease. &uot;Its accuracy compares favorably with other standards tests, such as routine urinalysis for urinary tract infection or PSA for prostate cancer. Even the gold standard for the diagnosis of AD -- postmortem histopathologic examination of the brain by a certified specialist -- is only between 84 percent to 92 percent reliable, based on comparisons between postmortem diagnosis by different specialists.&uot;

The book adds, &uot;The advent of the urinary version of the AD7C(TM) test has dramatically changed the (diagnostic) picture. Now a safe, painless and accurate test is available to aid the physician in the early stages of the investigation on other cause of dementia and other cognitive changes, such as adverse drug reactions, depression, and metabolic disorders.&uot;

Dr. Goldman is a physician and surgeon who also holds a doctorate in steroid biochemistry. Dr. Klatz is recognized as a leading authority in the new clinical science of Anti-Aging Medicine. He is founder and President of the American Longevity Research Institute, founded in 1984.

Dr. Michael Munzar, Medical Director of Nymox, commented, &uot;the accurate and complete discussion of Nymox's research into spherons and their relationship to Alzheimer's disease, and evaluation of the efficacy of the AD7C(TM) test, both have contributed to the better understanding of Nymox's role as a leader in research related both to detection and possibly a treatment for Alzheimer's. We are pleased that such distinguished physicians have added their voices to the growing acceptance by researchers and clinicians of Nymox's contributions in the fight against Alzheimer's disease.&uot;

Nymox Pharmaceutical Corporation pioneers in the research and development of products for the diagnosis and treatment of Alzheimer's disease, an affliction of more than 20 million people around the world. Nymox offers the world's only accurate, non-invasive test to aid in the diagnosis of the disease, and is developing proprietary Spheron-based drug therapies that could lead to effective treatment of Alzheimer's disease. Nymox also is developing unique drug therapies to treat E-coli infections and urinary tract infections, which have become highly resistant to conventional antibiotic treatments. Nymox Corp. is headquartered in Montreal, with a facility in Kensington, MD. Its stock is traded on Nasdaq with the symbol NYMX. More information is available at http://www.nymox.com.

This press release contains certain &uot;forward-looking statements,&uot; as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities.